Importantly, the study confirms XBP-1(S) as an essential regulator of BCL2 transcription, which is a prosurvival/antiapoptotic factor and confers resistance to aromatase therapy in breast cancer patients (Ding et al. 2003) (Fig. 4). This evidence concerns the gene XBP1 and breast carcinoma.